TMIC-40. A novel therapeutic strategy using a single non-toxic agent that produces consistent long-term control of orthotopic experimental glioblastomas
Lawrence D. Recht(Stanford University), Corinne Beinat(Stanford Medicine), Seema Nagpal(Stanford Medicine), Maria-Dorothea Nastke(International Data Group (United States)), Daniel M. Spielman(Stanford University), Ralph E. Hurd(Stanford University), Toni Cao(Neurosciences Institute), Laura Rosa Pisani(Regenxbio (United States)), Michael A. Kiebish(BG Medicine (United States)), Stéphane Gesta(Harvard University)
Cited by 0
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Evidence for a role of developmental genes in the origin of obesity and body fat distribution
|Proceedings of the National Academy of Sciences|2006|619
The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue
|Nature Medicine|2017|453
Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology
|Neoplasia|2018|446
12,13-diHOME: An Exercise-Induced Lipokine that Increases Skeletal Muscle Fatty Acid Uptake
|Cell Metabolism|2018|356